Depression in Parkinson's disease

Ideggyogyaszati Szemle

Volumn 67, Issue 7-8, 2014, Pages 229-236

  Rihmer, Zoltán ^a,b   Gonda, Xénia ^a,b,c   Döme, Peter ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Országos Pszichiátriai es Addiktológiai Intézet Öngyilkosság Kutató es Prevenciós Laboratórium   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Depression; Epidemiology; Parkinson's disease; Risk factors

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; PSYCHOTROPIC AGENT;

COGNITIVE THERAPY; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; TRANSCRANIAL MAGNETIC STIMULATION; BRAIN DEPTH STIMULATION; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; PREVALENCE; PSYCHOLOGY; CLINICAL FEATURE; PHOTOTHERAPY; SLEEP DEPRIVATION;

ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; COGNITIVE THERAPY; COMORBIDITY; DEEP BRAIN STIMULATION; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; HUMANS; PARKINSON DISEASE; PREVALENCE; RISK FACTORS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84906229898     PISSN: 00191442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373:2055-66.
2. Bower JH, Maraganore DM, McDonnell SDK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-20. (Pubitemid 29177924)
3. de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meché FG, Hofman A. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143-6. (Pubitemid 27100237)
4. Starkstein SE, Brockman S, Hayhow BD. Psychiatric syndromes in Parkinson's disease. Curr Opin Psychiatry 2012;25:468-72.
5. Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis 2012;46:581-9.
6. Chen JJ, Marsh L. Depression in Parkinson's Disease: Identification and Management. Pharmacotherapy 2013;33:972-83.
7. Benton JL, Wengel SP, Burke WJ. Depression in Parkinson's Disease: An Update. In: Pfeiffer RF, Bodis-Wollner I (eds.). Parkinson's Disease and Nonmotor Dysfunction, Current Clinical Neurology, New York: Springer Science+Business Media; 2013. p. 3-15.
8. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Ment Dis 1990;178:27-31. (Pubitemid 20175041)
9. Cummings JL. Depression and Parkinson's disease: A review. Am J Psychiatry 1992;149:443-54.
10. Robertson MM. Depression in neurological disorders. In: Robertson MM, Katona CLE (eds.). Depression and physical illness. Chichester: Wiley; 1997. p. 305-340.
11. Schuurman AG, van den Akker M, Ensinck KT, Metsemakers JF, Knottnerus JA, Leentjens AF, et al. Increased risk of Parkinson's disease after depression: A retrospective cohort study. Neurology 2002;58:1501-4. (Pubitemid 34552956)
12. Chen PH, Cheng SJ. Depression in Parkinson Disease: Current understanding and treatment. Internat J Gerontology 2008;2:172-82.
13. Costa FH, Rosso AL, Maultasch H, Nicaretta DH, Vincent MB. Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr 2012;70:617-20.
14. Rihmer Z, Sátori M, Pestality P. Selegiline - citalopram combination in patients with Parkinson's disease and major depression. Int J Psychiatry Clin Pract 2000;4:123-5. (Pubitemid 30421596)
15. Cannas A, Spissu A, Floris GL, Congia S, Saddi MV, Melis M, et al. Bipolar affective disorder and Parkinson's disease: a rare, insidious and often unrecognized association. Neurol Sci 2002;23 Suppl 2:S67-8. (Pubitemid 35355780)
16. Engmann B. Bipolar affective disorder and Parkinson's disease. Case Rep Med 2011:154165.
17. Chopra A, Tye SJ, Lee KH, Sampson S, Matsumoto J, Adams A, et al. Underlying neurobiology and clinical correlates of mania status after subthalamic nucleus deep brain stimulation in Parkinson's disease: a review of the literature. J Neuropsychiatry Clin Neurosci 2012;24:102-10.
18. Meric C, Pirdogan E, Günday Toker Ö, Tekin A, Bakim B, Celik S. Mania with Psychotic Feature Induced by The Use of Pramipexole in Parkinson's Disease: A Case Report. Turkish Journal of Psychiatry 2013; In press.
19. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-9. (Pubitemid 351311545)
20. Okun MS, Watts RL. Depression associated with Parkinson's disease: Clinical features and treatment. Neurology 2002;58(4 Suppl. 1):S63-S70. (Pubitemid 34163502)
21. Liberman A. Depression in Parkinson's disease - A review. Acta Neurol Scand 2006;113:1-8.
22. Hidasi Z, Salacz P, Csibri E. Depression in neuropsychiatric diseases. Ideggyogy Sz 2012;65:6-15.
23. Schreiber MA, Thompson AW. The pharmacologic management of depression in Parkinson's disease. Degenerative Neurological and Neuromuscular Disease 2013:3:1-9.
24. Even C, Weintraub D. Is depression in Parkinson's disease (PD) a specific entity? J Affect Disord 2012;139:103-12.
25. Latoo J, Mistry M, Dunne FJ. Depression in Parkinson's disease: diagnosis and management. Br J Hosp Med (Lond) 2012;73:331-4.
26. Schwarz J, Odin P, Buhmann C, Csoti I, Jost W, Wüllner U, et al. Depression in Parkinson's disease. J Neurol 2011;258(Suppl 2):S336-8.
27. Marsh L, McDonald WM, Cummings J, Ravina B; NINDS/NIMH Work Group on Depression and Parkinson's Disease. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006;21:148-58.
28. Assogna F, Fagioli S, Cravello L, Meco G, Pierantozzi M, Stefani A, et al. Depressive symptoms in Parkinson's disease and in non-neurological medical illnesses. Neuropsychiatr Dis Treat 2013;9:389-96.
29. Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J Psychopharmacol 2013;27:417-23.
30. Leentjens AF, Moonen AJ, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, et al. Modeling depression in Parkinson disease: Disease-specific and nonspecific risk factors. Neurology 2013;81:1036-43.
31. Cubo E, Benito-León J, Coronell C, Armesto D; ANIMO Study Group. Clinical correlates of apathy in patients recently diagnosed with Parkinson's disease: the ANIMO study. Neuroepidemiology 2012;38:48-55.
32. Foster PS, Drago V, Crucian GP, Sullivan WK, Rhodes RD, Shenal BV, et al. Anxiety and depression severity are related to right but not left onset Parkinson's disease duration. J Neurol Sci 2011;305:131-5.
33. Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual impairment, and Parkinson disease. Neurology 1981;31:645-50. (Pubitemid 11070445)
34. Shen CC, Tsai SJ, Perng CL, Kuo BI, Yang AC. Risk of Parkinson disease after depression: A nationwide population-based study. Neurology 2013 Oct 2. [Epub ahead of print].
35. Arabia G, Grossardt BR, Geda YE, Carlin JM, Bower JH, Ahlskog JE, et al. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Arch Gen Psychiatry 2007;64:1385-92. (Pubitemid 350223556)
36. Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease - epidemiology, mechanisms and management. Nat Rev Neurol 2011;8:35-47.
37. Robins AH. Depression in patients with parkinsonism. Brit J Psychiatry 1976;128:141-5.
38. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry 2005;76(Suppl 1):148-52.
39. Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011;95:163-212.
40. Mayeux R. Depression in the patient with Parkinson's disease. J Clin Psychiatry 1990;51(Suppl.):20-3. (Pubitemid 20231054)
41. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press; 1990.
42. Vriend C, Raijmakers P, Veltman DJ, van Dijk KD, van der Werf YD, Foncke EM, et al. Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry 2013 [Epub ahead of print].
43. Szot P, Franklin A, Raskind MA. The Noradrenergic System is a Major Component in Parkinson's Disease. In: Rana AQ (ed.). Etiology and Pathophysiology of Parkinson's Disease. InTech; 2011. p. 247-72.
44. Eskow Jaunarajs KL, Angoa-Perez M, Kuhn DM, Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neurosci Biobehav Rev 2011;35:556-64.
45. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-80.
46. Imamura K, Okayasu N, Nagatsu T. The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment. Acta Neurol Scand 2011;124:28-39.
47. Korchounov A, Winter Y, Rössy W. Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin Neuropharmacol 2012;35:121-4.
48. Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsis JH, Brown RP. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl, a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989;46:45-50. (Pubitemid 19038407)
49. Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994;51:607-15. (Pubitemid 24249102)
50. Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005;20:1161-9. (Pubitemid 41632203)
51. Dell'Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D'Avino C, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001;24:221-7. (Pubitemid 32717856)
52. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997;12:756-9. (Pubitemid 27406274)
53. Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F. The SSRI, citalopram improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol 2002;25:21-4. (Pubitemid 34178244)
54. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson's disease. Neurology 2012;78:1229-36.
55. Perez-Lloret S, Rascol O. Parkinson disease: Serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol 2012;8:365-6.
56. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992;53:278-82.
57. Kennedy GJ, Frazier A. Medical comorbidity and mental disorders in older adults. Curr Opin Psychiatry 1999;12:451-55. (Pubitemid 29515912)
58. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26 Suppl 3:S42-80.
59. Kaur N, Madan R, Sharma A. Successful use of rasagiline in combination with two antidepressants: a case report. Innov Clin Neurosci 2012;9:39-41.
60. da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 2008;111:351-9.
61. Landau AM, Clark C, Jivan S, Doudet DJ. Antiparkinsonian mechanism of electroconvulsive therapy in MPTP-lesioned non-human primates. Neurodegener Dis 2012;9:128-38.
62. Quinn DK, Rees C, Brodsky A, Deligtisch A, Evans D, Khafaja M, Abbott CC. Catatonia after deep brain stimulation successfully treated with lorazepam and right unilateral electroconvulsive therapy: A case report. J ECT 2013 Jul 15. [Epub ahead of print].
63. Tamás G, Takáts A, Radics P, Rózsa I, Csibri E, Rudas G, et al. Efficacy of deep brain stimulation in our patients with Parkinson's disease. Ideggyogy Sz 2013;66:115-20.
64. Ngoga D, Mitchell R, Kausar J, Hodson J, Harries A, Pall H. Deep brain stimulation improves survival in severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;[Epub ahead of print].
65. Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, et al CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010;362:2077-91.
66. Miocinovic S, Somayajula S, Chitnis S, Vitek JL. History, applications, and mechanisms of deep brain stimulation. JAMA Neurol 2013;70:163-71.
67. Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammerstad JP. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol 2005;62:554-60. (Pubitemid 40489885)
68. Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord 2010;25:2311-7.
69. Fregni F, Santos CM, Myczkowski ML, Rigolino R, Gallucci-Neto J, Barbosa ER, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:1171-4. (Pubitemid 39005779)
70. Epstein CM, Evatt ML, Funk A, Girard-Siqueira L, Lupei N, Slaughter L, et al. An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson's disease. Clin Neurophysiol 2007;118:2189-94. (Pubitemid 47386041)
71. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, Bienfait KL, Friedman J. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011;168:1066-74.
72. Dobkin RD, Menza M, Allen LA, Tiu J, Friedman J, Bienfait KL, et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol 2011;24:206-14.